Detection of Hepatic VX2 Tumors in Rabbits: Comparison of Conventional US and Phase-Inversion Harmonic US During the Liver-Specific Late Phase of Contrast Enhancement.
- Author:
Jeong Min LEE
1
;
Ji Hyun YOUK
;
Young Hwan LEE
;
Young Kon KIM
;
Chong Soo KIM
;
Chun Ai LI
Author Information
- Publication Type:Original Article
- Keywords: Animals, liver neoplasms; Liver neoplasms, US; Ultrasound (US), contrast media; Ultrasound (US), harmonic study
- From:Korean Journal of Radiology 2003;4(2):124-129
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: To compare phase-inversion sonography during the liver-specific phase of contrast enhancement using a microbubble contrast agent with conventional B-mode sonography for the detection of VX2 liver tumors. MATERIALS AND METHODS: Twenty-three rabbits, 18 of which had VX2 liver tumor implants, received a bolus injection of 0.6 g of Levovist (200 mg/ml). During the liver-specific phase of this agent, they were evaluated using both conventional sonography and contrast-enhanced phase-inversion harmonic imaging (CE-PIHI). Following sacrifice of the animals, pathologic analysis was performed and the reference standard thus obtained. The conspicuity, size and number of the tumors before and after contrast administration, as determined by a sonographer, were compared between the two modes and with the pathologic findings. RESULTS: CE-PIHI demonstrated marked hepatic parenchymal enhancement in all rabbits. For VX2 tumors detected at both conventional US and CE- PIHI, conspicuity was improved by contrast-enhanced PIHI. On examination of gross specimens, 52 VX2 tumors were identified. Conventional US correctly detected 18 of the 52 (34.6%), while PIHI detected 35 (67.3%) (p < 0.05). In particular, conventional US detected only three (8.3%) of the 36 tumors less than 10 mm in diameter, but CE-PIHI detected 19 such tumors (52.8%) (p < 0.05). CONCLUSION: Compared to conventional sonography, PIHI performed during the liver-specific phase after intravenous injection of Levovist is markedly better at detecting VX2 liver tumors.
